Logo image of 1PFE.MI

PFIZER INC (1PFE.MI) Stock Price, Forecast & Analysis

Europe - Euronext Milan - BIT:1PFE - US7170811035 - Common Stock

21.325 EUR
-0.16 (-0.72%)
Last: 12/23/2025, 7:00:00 PM

1PFE.MI Key Statistics, Chart & Performance

Key Statistics
Market Cap121.25B
Revenue(TTM)62.79B
Net Income(TTM)9.83B
Shares5.69B
Float5.68B
52 Week High27.3
52 Week Low18.73
Yearly Dividend1.44
Dividend Yield6.87%
EPS(TTM)2.72
PE7.84
Fwd PE8.06
Earnings (Next)02-02 2026-02-02/amc
IPO1944-01-17
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


1PFE.MI short term performance overview.The bars show the price performance of 1PFE.MI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4

1PFE.MI long term performance overview.The bars show the price performance of 1PFE.MI in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15

The current stock price of 1PFE.MI is 21.325 EUR. In the past month the price increased by 0.12%. In the past year, price decreased by -15.12%.

PFIZER INC / 1PFE Daily stock chart

1PFE.MI Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
SNW.DE SANOFI 10.84 200.10B
SAN.PA SANOFI 10.78 198.93B
1SAN.MI SANOFI 10.75 198.47B
MRK.DE MERCK KGAA 14.13 52.41B
1MRK.MI MERCK KGAA 13.94 51.72B
UCB.BR UCB SA 36.68 45.81B
UNC.DE UCB SA 37.51 46.84B
BAYN.DE BAYER AG-REG 6.73 35.31B
1BAYN.MI BAYER AG-REG 6.65 34.87B
REC.MI RECORDATI INDUSTRIA CHIMICA 24.71 10.18B
IPN.PA IPSEN 11.67 10.05B
TUB.BR FINANCIERE DE TUBIZE 100.72 9.32B

About 1PFE.MI

Company Profile

1PFE logo image Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

Company Info

PFIZER INC

66 Hudson Boulevard East

New York City NEW YORK US

Employees: 81000

1PFE Company Website

1PFE Investor Relations

Phone: 12127332323

PFIZER INC / 1PFE.MI FAQ

What does PFIZER INC do?

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.


What is the current price of 1PFE stock?

The current stock price of 1PFE.MI is 21.325 EUR. The price decreased by -0.72% in the last trading session.


Does 1PFE stock pay dividends?

PFIZER INC (1PFE.MI) has a dividend yield of 6.87%. The yearly dividend amount is currently 1.44.


What is the ChartMill technical and fundamental rating of 1PFE stock?

1PFE.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Should I buy 1PFE stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1PFE.MI.


How many employees does PFIZER INC have?

PFIZER INC (1PFE.MI) currently has 81000 employees.


What is the market capitalization of 1PFE stock?

PFIZER INC (1PFE.MI) has a market capitalization of 121.25B EUR. This makes 1PFE.MI a Large Cap stock.


1PFE.MI Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to 1PFE.MI. When comparing the yearly performance of all stocks, 1PFE.MI is a bad performer in the overall market: 77.52% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

1PFE.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to 1PFE.MI. While 1PFE.MI is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1PFE.MI Financial Highlights

Over the last trailing twelve months 1PFE.MI reported a non-GAAP Earnings per Share(EPS) of 2.72. The EPS increased by 24.03% compared to the year before.


Industry RankSector Rank
PM (TTM) 15.65%
ROA 4.71%
ROE 10.59%
Debt/Equity 0.62
Chartmill High Growth Momentum
EPS Q2Q%-17.92%
Sales Q2Q%-5.92%
EPS 1Y (TTM)24.03%
Revenue 1Y (TTM)3.9%

1PFE.MI Forecast & Estimates

For the next year, analysts expect an EPS growth of 2.02% and a revenue growth -0.89% for 1PFE.MI


Analysts
Analysts71.52
Price TargetN/A
EPS Next Y2.02%
Revenue Next Year-0.89%

1PFE.MI Ownership

Ownership
Inst Owners67.44%
Ins Owners0.02%
Short Float %N/A
Short RatioN/A